Management & Leadership

Over the last 25 years Andy has been actively involved in the virus and prion safety field, presenting at numerous regulatory agencies and conferences either in support of product registration or as an invited speaker at expert workshops and conferences. This has included presentations at the UK MHRA, German PEI, French AFFSAPS, US FDA, EMEA and PMDA (Japan) supporting regulatory submissions for various products. He has extensive experience in regulatory affairs and virus safety issues. He currently serves as an external expert for the EU SCENIHR committee on emerging human health risks, and continues to be a frequent presenter at international biopharmaceutical conferences.

In 2005 he founded ViruSure with the goal of providing a high quality testing service to the biopharmaceutical industry, a philosophy which remains a key focal point of the company.

He continued his postdoctoral activities at the Institute of Virology and eventually worked for a biotech company specializing in the development of encapsulated cell based therapies for the treatment of cancers. There he was responsible for regulatory submissions and the outsourced production. In parallel he studied tumor biology and pharmaceutical quality management. He therefore comes with significant experience in the GMP testing of cell-based therapeutics. Walter joint ViruSure in 2008 and is responsible for the management of the in-vitro testing services.

At Baxter Angelika held positions in the Vaccine, Plasma and Biosurgery divisions focussing on molecular diagnostics, cell culture and in-vivo based tests for virus and bacteria as well as being Head of an analytical QC lab. She also supported the company piChem R&D in Graz to establish GMP systems. From 2005 till 2010 Angelika served as lead auditor for GLP and GMP inspections for the AGES PharmMed responsible for inspections both within Austria as well as inspections in cooperation with other international authorities including the EMA, OECD and WHO. She continues to serve as external expert to the WHO assisting in inspections ensuring a safe and secure supply of medical products for critical therapies (e.g. AIDS, Malaria, Tuberculosis) in developing countries.

Angelika joined ViruSure in September 2010 as Quality Manager with overall responsibility for maintaining and developing the ViruSure quality systems to ensure a continued high level of quality for our testing services.

She joined ViruSure in 2007 and worked for a number of years as a GLP study director performing virus and prion clearance studies, before taking over the responsibility for the set up and running of the in vitro GMP labs in 2016. With her considerable experience of both upstream and downstream biosafety testing Tiffany took on the role of Head of Testing services at ViruSure in 2024 and is responsible for the conduct of in vitro testing services at the TechGate facility.

Parallel to her scientific career, Katrin kept a strong focus on her training as a professional laboratory animal specialist – she is a FELASA C certified veterinarian. At ViruSure, Katrin is responsible for the conduction of in vivo experiments and the management of our in vivo team at our new GMP/GLP certified Animal Facility situated not far from Tech Gate.

Prior to his position at ViruSure he has worked at several other CRO´s (BioReliance, Invitrogen, NewLab BioQuality and Charles River Laboratories). At BioReliance he was a Study Director for virus validation studies before moving into the role of a key account manager for biosafety testing services.

A graduate of the University of Heidelberg with a degree in Genetics, Microbiology and Biochemistry, he served for 4 years at a diagnostic laboratory establishing ELISA and PCR tests for virus and autoimmune diagnostics. He earned his Ph.D in virology at the German Cancer Research Centre in Heidelberg working on Hepatitis B Virus at the Institute for Applied Tumour Virology (headed by 2008 Nobel Prize winner Prof. Harald zur Haussen). Ralf holds a patent on a p53 ELISA test.

She performed her post-doctoral research in stem cell therapies for the treatment of neurodegenerative diseases with the support of Marie-Curie Fellowship. In 2012, Marina joined the company nLife Therapeutics, a biotech company developing therapeutic oligonucleotides, as Head of Laboratory. Afterwards, Marina moved into the Biologics CMO sector, first at Stemmatters as Project Manager and then as Business Development Manager at 3P Biopharmaceuticals.

Marina joined ViruSure’s team in 2020 as Business Development Manager bringing experience in ATMP development as well as in biopharmaceuticals and is responsible for customers in Portugal, Spain and North/South America.